These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

976 related articles for article (PubMed ID: 30548363)

  • 21. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
    Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
    Mignon S; Willard-Gallo K; Van den Eynden G; Salgado R; Decoster L; Marien KM; Vansteenkiste JF; Teugels E; De Grève J
    Pathol Oncol Res; 2020 Apr; 26(2):1221-1228. PubMed ID: 31228073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
    Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
    Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.
    Duverger L; Osio A; Cribier B; Mortier L; De Masson A; Basset-Seguin N; Lebbé C; Battistella M
    Cancer Immunol Immunother; 2019 Jun; 68(6):951-960. PubMed ID: 30953116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma.
    Faraj SF; Munari E; Guner G; Taube J; Anders R; Hicks J; Meeker A; Schoenberg M; Bivalacqua T; Drake C; Netto GJ
    Urology; 2015 Mar; 85(3):703.e1-6. PubMed ID: 25733301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
    Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
    Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR; Milne K; Kroeger DR; Nelson BH
    Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
    Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F
    Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed death ligand 1 expression and CD8
    Zhou J; Gong Z; Jia Q; Wu Y; Yang ZZ; Zhu B
    Biochem Biophys Res Commun; 2018 Apr; 498(4):751-757. PubMed ID: 29526752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of a PD-L1/PD-1/CD8 axis-based classifier to predict cancer survival of upper tract urothelial carcinoma after radical nephroureterectomy.
    Chen J; Zhong W; Yang M; Hou W; Wang X; Xia K; Yu H; Yang M; Zhou B; Wang B; Huang J; Lin T
    Cancer Immunol Immunother; 2021 Sep; 70(9):2657-2668. PubMed ID: 33606065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
    Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed death-ligand 1 and tumor-infiltrating lymphocytes (TILs) - low TIL density may predict poorer long-term prognosis in T1 laryngeal cancer.
    Pakkanen P; Ilmarinen T; Halme E; Irjala H; Koivunen P; Pukkila M; Ventelä S; Almangush A; Birkman EM; Lindgren O; Pohjolainen V; Sjöblom N; Haglund C; Hagström J; Aaltonen LM
    Virchows Arch; 2024 Aug; 485(2):315-322. PubMed ID: 37462760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma.
    Sato F; Ono T; Kawahara A; Matsuo K; Kondo R; Sato K; Akiba J; Kawaguchi T; Kakuma T; Chitose SI; Umeno H; Yano H
    Laryngoscope; 2021 May; 131(5):E1481-E1488. PubMed ID: 33022760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.